AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38682750 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV-seropositive donor and EBV-naïve recipient (D+R-)
Number of subjects: 944
Study 38682750 — intervention group
Group type: EXPERIMENTAL
Intervention: D+R-
Number of subjects: 944
Study 38682750 — intervention group
Group type: EXPERIMENTAL
Intervention: Monomorphic/polymorphic PTLD (n=21)
Number of subjects: 944
Study 38682750 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-liver transplant recipients with monomorphic/polymorphic PTLD
Number of subjects: 944
Study 38682758 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial interventions (brief interventions ranging from a single session of 10 to 60 minutes to five sessions of 10 minutes each)
Number of subjects: 1369
Study 38682758 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) or similar treatments (comprehensive assessment of alcohol use and advice to stop drinking during pregnancy)
Number of subjects: 1369
Study 38682786 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors (ACEi)
Number of subjects: 28341
Study 38682786 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin receptor blockers (ARB)
Number of subjects: 28341
Study 38682786 — intervention group
Group type: COMPARATOR
Intervention: ARB
Number of subjects: 28341
Study 38682903 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Southwestern Aneurysm Severity Index (mSASI) model
Number of subjects: 242
Study 38683027 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed 200-mg cenobamate tablet administered orally
Number of subjects: 0
Study 38683027 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed 200-mg cenobamate tablet administered via nasogastric tube
Number of subjects: 0
Study 38683027 — intervention group
Group type: COMPARATOR
Intervention: Intact 200-mg cenobamate tablet
Number of subjects: 0
Study 38683145 — intervention group
Group type: EXPERIMENTAL
Intervention: MP0533 (multispecific CD3-engaging DARPin)
Number of subjects: 0
Study 38683158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Number of subjects: 0
Study 38683158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry plus clinical decision support algorithms (CDSA)
Number of subjects: 0
Study 38683158 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 38683158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-post study in Kenya and Senegal
Number of subjects: 0
Study 38683158 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 0
Study 38683439 — intervention group
Group type: EXPERIMENTAL
Intervention: EUROIA scale
Number of subjects: 231
Study 38683439 — intervention group
Group type: COMPARATOR
Intervention: KCCQ-OS
Number of subjects: 231
Study 38683479 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once daily
Number of subjects: 1789
Study 38683479 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg biweekly
Number of subjects: 1789
Study 38683479 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 1789
Study 38683495 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI7247
Number of subjects: 67
Study 38683596 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg once daily for 5 years
Number of subjects: 3020
Study 38683596 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 5 years
Number of subjects: 3020
Study 38683602 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Number of subjects: 142
Study 38683602 — intervention group
Group type: EXPERIMENTAL
Intervention: Solanezumab
Number of subjects: 142
Study 38683602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 38683612 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Number of subjects: 48
Study 38683612 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 48
Study 38683663 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month blended refresher training (Mixed6 group)
Number of subjects: 1163
Study 38683663 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month traditional refresher training (Traditional6 group)
Number of subjects: 1163
Study 38683663 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month blended refresher training (Mixed12 group)
Number of subjects: 1163
Study 38683663 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month blended refresher training (Blended6 group)
Number of subjects: 1163
Study 38683665 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app-based intervention with Bluetooth-connected monitoring devices and feedback system (n=39)
Number of subjects: 77
Study 38683665 — intervention group
Group type: COMPARATOR
Intervention: Control group with conventional non-Bluetooth devices (n=38)
Number of subjects: 77
Study 38683966 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-1 TCR-T therapy after lymphodepleting chemotherapy
Number of subjects: 9
Study 38684039 — intervention group
Group type: EXPERIMENTAL
Intervention: Unesbulin 300 mg administered orally twice per week plus DTIC 1,000 mg/m
Number of subjects: 0
Study 38684046 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 1 mg daily for 12 weeks
Number of subjects: 142
Study 38684046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 38684080 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient partnership tools including a 1-page visit preparation guide and a library of short educational videos on medication safety.
Number of subjects: 405
Study 38684080 — intervention group
Group type: COMPARATOR
Intervention: Usual care during control periods.
Number of subjects: 405
Study 38684089 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital self-disclosure intervention (4 phases, face-to-face)
Number of subjects: 84
Study 38684089 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 84
Study 38684193 — intervention group
Group type: EXPERIMENTAL
Intervention: Traction-assisted endoscopic submucosal dissection (ESD)
Number of subjects: 106
Study 38684230 — intervention group
Group type: EXPERIMENTAL
Intervention: MYTX-011
Number of subjects: 0
Study 38684243 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (dilution to 0.016 mg/mL) using an electric syringe pump at a rate of 0.48 mg/h (30 mL/h) from the start of anaesthesia, titrated to achieve haemodynamic target.
Number of subjects: 500
Study 38684243 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine, manual titration with a maximal dose of 30 mg, followed by perfusion with norepinephrine.
Number of subjects: 500
Study 38684260 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal nightly positional therapy (PT)
Number of subjects: 167
Study 38684260 — intervention group
Group type: COMPARATOR
Intervention: Sham positional therapy (sham-PT)
Number of subjects: 167
Study 38684265 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (oral Vitamin D3 50,000 IU/week for 4 weeks, then 50,000 IU once every 2 weeks for 52 weeks)
Number of subjects: 220
Study 38684265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 38684276 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary stopping eating and drinking (VSED)
Number of subjects: 37500
Study 38684276 — intervention group
Group type: EXPERIMENTAL
Intervention: Independently taking lethal medication attended by a confidant (ILMC)
Number of subjects: 37500
Study 38684277 — intervention group
Group type: EXPERIMENTAL
Intervention: CMNT diet with specific meal replacement Chinese medicinal foods (6 cycles of 5 consecutive days followed by 10 days of regular food intake)
Number of subjects: 120
Study 38684277 — intervention group
Group type: COMPARATOR
Intervention: Usual care group with standard dietary advice
Number of subjects: 120
Study 38684277 — intervention group
Group type: EXPERIMENTAL
Intervention: CMNT diet
Number of subjects: 120
Study 38684277 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 120
Study 38684558 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial risk communication intervention
Number of subjects: 512
Study 38684631 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovo-cel gene therapy
Number of subjects: 0
Study 38684631 — intervention group
Group type: COMPARATOR
Intervention: Common care
Number of subjects: 0
Study 38684670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment regimen for high-risk SMM patients
Number of subjects: 57
Study 38684670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment regimen for ultra-high risk (UHR) SMM patients
Number of subjects: 57
Study 38684860 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-enabled electrocardiogram (ECG) alert intervention
Number of subjects: 15965
Study 38684860 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15965
Study 38684860 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-enabled ECG alert intervention in patients with high-risk ECGs
Number of subjects: 15965
Study 38684860 — intervention group
Group type: COMPARATOR
Intervention: Control group for high-risk ECGs
Number of subjects: 15965
Study 38684918 — intervention group
Group type: EXPERIMENTAL
Intervention: Optilume BPH Catheter System
Number of subjects: 148
Study 38684918 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 148
Study 38684956 — intervention group
Group type: COMPARATOR
Intervention: Cerebellar deep brain stimulation (DBS) in the dorsal dentate nucleus, using Medtronic Percept neurostimulator, with effective stimulation for one month followed by sham stimulation for one month in a random order.
Number of subjects: 10
Study 38684956 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group) for one month followed by effective stimulation for one month in a random order.
Number of subjects: 10
Study 38684956 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar DBS
Number of subjects: 10
Study 38685016 — intervention group
Group type: EXPERIMENTAL
Intervention: AKL-T01
Number of subjects: 479
Study 38685017 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient Parenteral Antimicrobial Therapy (OPAT)
Number of subjects: 58
Study 38685032 — intervention group
Group type: EXPERIMENTAL
Intervention: HPI-guided hemodynamic management using the Hemosphere platform and AcumenIQ® sensor (Edwards Lifesciences)
Number of subjects: 0
Study 38685032 — intervention group
Group type: EXPERIMENTAL
Intervention: HPI-guided hemodynamic management
Number of subjects: 0
Study 38685042 — intervention group
Group type: EXPERIMENTAL
Intervention: Marfan syndrome (MFS) group
Number of subjects: 63
Study 38685042 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy children
Number of subjects: 63
Study 38685109 — intervention group
Group type: EXPERIMENTAL
Intervention: MMS for 180 days with one 180-count tablet bottle (MMS-180)
Number of subjects: 1545
Study 38685109 — intervention group
Group type: COMPARATOR
Intervention: IFA for 90 days (IFA-90)
Number of subjects: 1545
Study 38685109 — intervention group
Group type: EXPERIMENTAL
Intervention: MMS for 180 days with two distributions of 90-count tablet bottles (MMS-90)
Number of subjects: 1545
Study 38685119 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with dense breasts (n=647)
Number of subjects: 969
Study 38685119 — intervention group
Group type: EXPERIMENTAL
Intervention: All women surveyed (n=969)
Number of subjects: 969
Study 38685119 — intervention group
Group type: COMPARATOR
Intervention: Women with non-dense breasts vs. dense breasts
Number of subjects: 969
Study 38685119 — intervention group
Group type: COMPARATOR
Intervention: Women receiving chemotherapy
Number of subjects: 969
Study 38685119 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who previously delayed breast cancer treatment more than 3 months
Number of subjects: 969
Study 38685123 — intervention group
Group type: EXPERIMENTAL
Intervention: Miracle Friends
Number of subjects: 760
Study 38685123 — intervention group
Group type: EXPERIMENTAL
Intervention: Miracle Money
Number of subjects: 760
Study 38685123 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 760
Study 38685291 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Activity and Pain Education (GAPE)
Number of subjects: 144
Study 38685291 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 144
Study 38685376 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroprognostication guidelines adherence
Number of subjects: 30
Study 38685376 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of life-sustaining therapies (WLST)
Number of subjects: 30
Study 38685376 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal testing
Number of subjects: 30
Study 38685376 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical gestalt
Number of subjects: 30
Study 38685376 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective diagnostics
Number of subjects: 30
Study 38685400 — intervention group
Group type: EXPERIMENTAL
Intervention: Total diet replacement (TDR) with low-energy nutritionally complete formula products for 12 weeks and behavioural support
Number of subjects: 56
Study 38685400 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 56
Study 38685464 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized clinical decision support (CDS)
Number of subjects: 1145
Study 38685464 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1145
Study 38685481 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-g out-of-hospital TXA bolus
Number of subjects: 541
Study 38685481 — intervention group
Group type: COMPARATOR
Intervention: 1-g out-of-hospital TXA bolus/1-g in-hospital TXA infusion
Number of subjects: 541
Study 38685481 — intervention group
Group type: COMPARATOR
Intervention: Out-of-hospital saline bolus/in-hospital saline infusion (placebo)
Number of subjects: 541
Study 38685704 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular overdentures retained by four titanium-zirconium mini implants
Number of subjects: 74
Study 38685704 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless protocol
Number of subjects: 74
Study 38685704 — intervention group
Group type: EXPERIMENTAL
Intervention: Less resorbed ridges
Number of subjects: 74
Study 38685855 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of life stressors
Number of subjects: 81
Study 38685855 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressors with greater severity
Number of subjects: 81
Study 38685855 — intervention group
Group type: COMPARATOR
Intervention: Absence of life stressors
Number of subjects: 81
Study 38685868 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of sentinel lymph node biopsy (SLNB) after breast-conserving surgery (BCS) in patients showing BpCR after NACT.
Number of subjects: 178
Study 38685922 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 46
Study 38685922 — intervention group
Group type: COMPARATOR
Intervention: Intensive non-surgical treatment
Number of subjects: 46
Study 38685921 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentralisation of TB diagnostics to primary health centres (PHC) and district hospitals (DH) with a comprehensive diagnosis package including tuberculosis screening, clinical evaluation, Xpert Ultra-testing, and chest radiography.
Number of subjects: 255512
Study 38685921 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentralisation in DH-focused districts.
Number of subjects: 255512
Study 38685921 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentralisation in PHC-focused districts.
Number of subjects: 255512
Study 38685921 — intervention group
Group type: COMPARATOR
Intervention: Pre-intervention period.
Number of subjects: 255512
Study 38685927 — intervention group
Group type: EXPERIMENTAL
Intervention: iTalkBetter (self-led app utilizing confrontation naming therapy)
Number of subjects: 27
Study 38685927 — intervention group
Group type: EXPERIMENTAL
Intervention: iTalkBetter (self-led app)
Number of subjects: 27
Study 38685930 — intervention group
Group type: COMPARATOR
Intervention: DH-focused strategy
Number of subjects: 0
Study 38685930 — intervention group
Group type: COMPARATOR
Intervention: PHC-focused strategy
Number of subjects: 0
Study 38685972 — intervention group
Group type: EXPERIMENTAL
Intervention: inetetamab and pyrotinib (240 mg, 320 mg)
Number of subjects: 48
Study 38685972 — intervention group
Group type: EXPERIMENTAL
Intervention: inetetamab and pyrotinib
Number of subjects: 48
Study 38686016 — intervention group
Group type: EXPERIMENTAL
Intervention: Dato-DXd + durvalumab
Number of subjects: 1075
Study 38686016 — intervention group
Group type: EXPERIMENTAL
Intervention: Dato-DXd monotherapy
Number of subjects: 1075
Study 38686016 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice of therapy (ICT; capecitabine, pembrolizumab, or capecitabine and pembrolizumab)
Number of subjects: 1075
Study 38686207 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-125 seed implantation
Number of subjects: 36
Study 38686220 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy donor stool FMT
Number of subjects: 46
Study 38686220 — intervention group
Group type: COMPARATOR
Intervention: Placebo (own stool)
Number of subjects: 46
Study 38686365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg) administered intravenously post-surgery
Number of subjects: 0
Study 38686450 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 mcg bd daily for 4 weeks
Number of subjects: 30
Study 38686450 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study 38686621 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Cognitive Training (CT), n = 60, duration: 10 weeks
Number of subjects: 124
Study 38686621 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Cognitive Training (CT)
Number of subjects: 124
Study 38686621 — intervention group
Group type: COMPARATOR
Intervention: Casual Game Training (active control, AC), n = 64
Number of subjects: 124
Study 38686814 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in extensor strength
Number of subjects: 279
Study 38686814 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized extensor strength
Number of subjects: 279
Study 38686814 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensor/flexor ratio changes
Number of subjects: 279
Study 38686863 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary microvascular dysfunction (CMD) defined as index of microcirculatory resistance ≥25 or coronary flow reserve <2.0 with normal fractional flow reserve; measured at 3 months post-STEMI.
Number of subjects: 210
Study 38686863 — intervention group
Group type: COMPARATOR
Intervention: No CMD (control group).
Number of subjects: 210
Study 38686879 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor inhibitor initiation
Number of subjects: 66
Study 38686933 — intervention group
Group type: EXPERIMENTAL
Intervention: EsoCheck/EsoGuard
Number of subjects: 243
Study 38686961 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral artery cannulation
Number of subjects: 3751
Study 38686961 — intervention group
Group type: COMPARATOR
Intervention: Supra-aortic arterial cannulation
Number of subjects: 3751
Study 38686961 — intervention group
Group type: COMPARATOR
Intervention: Direct aortic cannulation
Number of subjects: 3751
Study 38686961 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching of the primary site of arterial cannulation
Number of subjects: 3751
Study 38687061 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic intervention (mixture of four probiotic strains with galacto-oligosaccharides) administered to mothers from the 36th week of pregnancy and to infants until 6 months of age.
Number of subjects: 0
Study 38687136 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette inhalation
Number of subjects: 0
Study 38687136 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38687158 — intervention group
Group type: EXPERIMENTAL
Intervention: immobilization + action observation/mental imagery (AOMI)
Number of subjects: 39
Study 38687158 — intervention group
Group type: EXPERIMENTAL
Intervention: immobilization + neuromuscular electrical stimulation (NMES)
Number of subjects: 39
Study 38687158 — intervention group
Group type: COMPARATOR
Intervention: immobilization only
Number of subjects: 39
Study 38687158 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 39
Study 38687339 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Cold Atmospheric Plasma treatment, applied once or twice a week
Number of subjects: 0
Study 38687482 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-to-peer support intervention
Number of subjects: 2077
Study 38687482 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2077
Study 38687481 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4-mg aflibercept injection
Number of subjects: 100
Study 38687481 — intervention group
Group type: COMPARATOR
Intervention: Laser therapy
Number of subjects: 100
Study 38687582 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital approaches (such as gamification, photoverification system, and digital media) to generate demand for HIVST and avoid risks associated with attending clinics
Number of subjects: 125
Study 38687582 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness and sensitization through existing infrastructures (such as churches, schools, and health facilities)
Number of subjects: 125
Study 38687582 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnerships with influencers, role models, and leaders (such as religious and youth leaders and social influencers in businesses, churches, organizations, and schools)
Number of subjects: 125
Study 38687693 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational training by a multidisciplinary team at hospital discharge and follow-up phone recall for therapy adherence.
Number of subjects: 360
Study 38687693 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 360
Study 38687742 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized physical exercise protocol based on clinical and objective assessments.
Number of subjects: 100
Study 38687742 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention.
Number of subjects: 100
Study 38687741 — intervention group
Group type: EXPERIMENTAL
Intervention: Schroth treatment (Standard care + Schroth treatment)
Number of subjects: 124